A pediatric case of new delhi metallo-β-lactamase-1-producing enterobacteriaceae in the united states

Pediatric Infectious Disease Journal

Volumn 32, Issue 11, 2013, Pages 1291-1294

  Green, Daniel A ^a,b   Srinivas, Nivedita ^a   Watz, Nancy ^b   Tenover, Fred C ^a,c   Amieva, Manuel ^b   Banaei, Niaz ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

carbapenemase; drug resistance; New Delhi metallo ? lactamase; pediatrics

Indexed keywords

ACICLOVIR; AMIKACIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFOXITIN; CEFTRIAXONE; ERTAPENEM; ESTERASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEUKOCYTE ESTERASE; MEROPENEM; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE 1; NITRITE; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; STEROID; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARM MOVEMENT; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BRAIN DAMAGE; CASE REPORT; CHILD; DIPLOPIA; DISK DIFFUSION; DRUG WITHDRAWAL; DYSARTHRIA; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; FEVER; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HORMONAL THERAPY; HOSPITAL READMISSION; HUMAN; HYPERTENSION; INDIA; INVOLUNTARY MOVEMENT; LEUKOCYTE COUNT; LOADING DRUG DOSE; LUMBAR PUNCTURE; METALLO BETA LACTAMASE 1 PRODUCING ENTEROBACTERIACEAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEUROGENIC BLADDER; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; PARIETAL LOBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; UNITED STATES; URINALYSIS; URINE CULTURE; WEAKNESS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CHILD; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; UNITED STATES;

EID: 84886947981     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829eca34     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. New carbapenem-resistant Enterobacteriaceae warrant additional action by healthcare providers. Health Alert Network. 2013; CDCHAN-00341.
2. Wilson ME, Chen LH. NDM-1 and the role of travel in its dissemination. Curr Infect Dis Rep. 2012;14:213-226.
3. Centers for Disease Control and Prevention. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:750.
4. Centers for Disease Control and Prevention. Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012. MMWR Morb Mortal Wkly Rep. 2012;61:446-448.
5. Mochon AB, Garner OB, Hindler JA, et al. New Delhi metallo-beta-lactamase (NDM-1)-producing K. pneumoniae: case report and laboratory detection strategies. J Clin Microbiol. 2011;49:1667-1670.
6. Clinical and Laboratory Standards Institute. M100-S22-U. Performance Standards for Antimicrobial Susceptibility Testing: 22nd Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
7. Hindiyeh M, Smollen G, Grossman Z, et al. Rapid detection of blaKPC carbapenemase genes by real-time PCR. J Clin Microbiol. 2008;46:2879-2883.
8. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo- beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in K. pneumoniae sequence type 14 from India. Antimicrob Agents Chemo. 2009;53:5046-5054.
9. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-602.
10. Doyle D, Peirano G, Lascols C, et al. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol. 2012;50:3877-3880.
11. Ong DC, Koh TH, Syahidah N, et al. Rapid detection of the blaNDM-1 gene by real-time PCR. J Antimicrob Chemother. 2011;66:1647-1649.
12. Smith MA, Bidochka MJ. Bacterial fitness and plasmid loss: the importance of culture conditions and plasmid size. Can J Microbiol. 1998;44:351-355.
13. Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother. 2010;65:1311-1312.
14. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
15. Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents. 2013;41:110-116.
16. Spanu T, De Angelis G, Cipriani M, et al. In vivo emergence of tigecycline resistance in multidrug-resistant K. pneumonaie and Escherichia coli. AAC. 2012;56:4516-4518.
17. Ruzin A, Visali MA, Keeney D, et al. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in K. pneumoniae. AAC. 2005;49:1017-1022.
18. Rosenblum R, Khan E, Gonzalez G, et al. Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae. Int J Antimicrob Agents. 2011;38:39-45.
19. Veleba M, Schneiders T. Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56:4466-4467.
20. Food and Drug Administration. FDA drug safety communication: increased risk of death with tigecycline compared to other antibiotics used to treat similar infections. Available at http://www.fda.gov/DrugsSafety/ucm224370. htm. Accessed February 14, 2013.
21. Monurol [package insert]. St. Louis, MO: Forest Pharmaceuticals Inc; 1997.